Shots:
- Bio-Thera & World Medicine entered into an exclusive license & commercialization agreement for BAT2206, a biosimilar to Janssen’s Stelara (ustekinumab), leveraging
- World Medicine’s marketing expertise & distribution network in Turkey
As per the terms, World Medicine will hold market approval of BAT2206 in Turkey as well as its registration, imports, promotion & marketing, while Bio-Thera will handle the commercial supply & manufacturing in its Guangzhou facilities - In addition, Bio-Thera has submitted MAA for BAT2206 to China’s NMPA, EMA & the US FDA
Ref: Biothera | Image: Biothera & World Medicine
Related News:- Candid Therapeutics Partners with EpimAb Biotherapeutics to Develop T-Cell Engagers for Autoimmune Indications
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
